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Abstract
Motivation: Finding computationally drug–target interactions (DTIs) is a convenient strategy to
identify new DTIs at low cost with reasonable accuracy. However, the current DTI prediction meth-
ods suffer the high false positive prediction rate.
Results: We developed DDR, a novel method that improves the DTI prediction accuracy. DDR is
based on the use of a heterogeneous graph that contains known DTIs with multiple similarities
between drugs and multiple similarities between target proteins. DDR applies non-linear similarity
fusion method to combine different similarities. Before fusion, DDR performs a pre-processing step
where a subset of similarities is selected in a heuristic process to obtain an optimized combination
of similarities. Then, DDR applies a random forest model using different graph-based features
extracted from the DTI heterogeneous graph. Using 5-repeats of 10-fold cross-validation, three test-
ing setups, and the weighted average of area under the precision-recall curve (AUPR) scores, we
show that DDR significantly reduces the AUPR score error relative to the next best start-of-the-art
method for predicting DTIs by 31% when the drugs are new, by 23% when targets are new and by
34% when the drugs and the targets are known but not all DTIs between them are not known.
Using independent sources of evidence, we verify as correct 22 out of the top 25 DDR novel predic-
tions. This suggests that DDR can be used as an efficient method to identify correct DTIs.
Availability and implementation: The data and code are provided at https://bitbucket.org/RSO24/ddr/.
Contact: vladimir.bajic@kaust.edu.sa
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Drug discovery is the process through which potential beneficial
treatment effects or medical uses of a new drug candidate are identi-
fied. Distinct phases of drug discovery and development define the
initial stage of target identification and validation, compound leads
identification, validation and optimization, and different types of
preclinical and clinical trials until the final approval by the Food
and Drug Administration (FDA) (Paul et al., 2010) is reached.
Drugs function through interaction with various molecular targets.
We call such interaction drug–target interactions (DTIs). Proteins
are one useful group of such targets. Through binding, drugs can
either enhance or inhibit functions carried out by proteins
(Overington et al., 2006; Santos et al., 2017) and thus affect the dis-
ease conditions. Bringing a new drug to the market is a highly chal-
lenging and complex process in terms of time and cost. Moreover,
the number of newly approved drugs by the FDA is decreasing, illus-
trating the productivity decline in drug discovery and development
(Swinney and Anthony, 2011). However, studies showed that most
VC The Author 2017. Published by Oxford University Press. 1164
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of the FDA-approved drug molecules exhibit poly-pharmacological
properties, i.e. drugs can have interaction with multiple targets,
which are not their primary therapeutic targets (i.e. drugs have off-
target molecules) (Cichonska et al., 2015), and this is frequently the
major cause of undesirable side-effects. One interesting and useful
objective is to link the newly identified DTIs of a known drug to the
treatment of diseases that are different from diseases for which the
drug has been originally developed (Cichonska et al., 2015; Li et al.,
2016; Shim and Liu, 2014). The availability of public biomedical
databases along with the development of computational approaches
has made it possible to provide useful frameworks to partially over-
come limitations of the traditional experimental approaches (Vilar
and Hripcsak, 2016) and help in finding a new association for the
existing drugs with off-target effects. Identifying computationally
highly likely DTIs for a known drug can be then employed to iden-
tify potential new uses of the drug in question, and this makes a use-
ful strategy in drug repurposing (Chen et al., 2016; Daminelli et al.,
2015; Wu et al., 2017). A part of such solution is the identification
of novel DTIs that play an important role in the discovery of addi-
tional applications for known drugs, as well as in the understanding
of drug’s modes of action (Overington et al., 2006; Santos et al.,
2017; Schenone et al., 2013). This necessitates development of accu-
rate computational approaches to focus on a smaller number of
highly likely targets of a drug for the follow-up experimental valida-
tion. However, predicting correct DTI is not sufficient for itself to
infer what effect such interaction may have. Additional steps may be
needed, such as, for example, to show inhibition of target expres-
sion. One approach for computationally inferring such effects may
be the utilization of predictive models of activity in appropriate bio-
logical assays (Soufan et al., 2016; Soufan et al., 2015) as those in
the PubChem resource. As summarized in recent reviews (Chen
et al., 2016; Santos et al., 2017), a wide range of databases, web
tools and computational methods have emerged with the potential
to predict DTIs by learning from interaction data supplemented
with information on the similarities among drugs and similarities
among proteins (Daminelli et al., 2015; Wu et al., 2017). However,
confirming whether a drug could interact with a target protein
requires an additional effort. This is owing to the relatively limited
information about interactions between drugs and target proteins
(Dobson, 2004; Kanehisa et al., 2006; Menni et al., 2017), as well
as the poor characterization of proteins as drug targets (Santos
et al., 2017).
Early attempts in computational prediction of DTIs can be cate-
gorized into two main groups and include docking simulations and
ligand-based approaches (Cheng et al., 2007; Keiser et al., 2007).
Docking methods consider the 3D structure of target proteins.
However, this approach is extensively time-consuming, and the
structural information of targets is not available for all target proteins.
Ligand-based methods compare a query ligand with a set of known
ligands with target proteins. However, it may not perform well in
cases the number of known ligands with target proteins is small.
Public data sources have promoted the development of various
strategies for repurposing drugs including genome, phenome, drug
chemical structures, biological interactome, biomedical literature
text and biological bioassays (Li et al., 2016). Moreover, the accessi-
bility of big data sources, through several databases and biomedical
literature of DTI information, provide a useful way to extract differ-
ent biological interaction profiles and signatures (or descriptors) of
drugs and target proteins to discover novel DTIs (Ba-Alawi et al.,
2016; Cheng et al., 2012a,b; Ding et al., 2014; Mitchell, 2001;
Perlman et al., 2011; Vilar and Hripcsak, 2016; Wu et al., 2017;
Yamanishi et al., 2010). On the basis of the guilt-by-association
principle, in which chemically similar drugs tend to interact with
similar proteins, many methods have been proposed for DTI predic-
tion based on the consideration of similarity measures between
drugs or similarities between proteins. Such prediction methods are
based on graph inference (Alaimo, 2013; Ba-Alawi et al., 2016;
Bleakley and Yamanishi, 2009; Chen et al., 2012a,b; Seal et al.,
2015; Wang et al., 2013), machine-learning algorithms (Hao et al.,
2017; Lim et al., 2016; Liu et al., 2016; Mei et al., 2013; Perlman
et al., 2011; Soufan et al., 2016; van Laarhoven et al., 2011; Yuan
et al., 2016), text mining (Zhu et al., 2005) and semantic linked
data (Chen et al., 2012a; Fu et al., 2016; Tari and Patel, 2014; Zhu
et al., 2014).
Recently, several methods are developed to integrate heterogene-
ous information related to the drug, target protein, and their interac-
tion data, to provide effective and efficient ways to predict new
DTIs (Hao et al., 2017; Mei et al., 2013). These methods utilize var-
ious types of profiles for drugs and proteins constructed with differ-
ent biological data. Such DTI prediction methods were developed
based on the idea of utilizing heterogeneous networks of known
DTIs, similarity between drugs and similarity between target pro-
teins (Hao et al., 2017; Nascimento et al., 2016; Perlman et al.,
2011; Zong et al., 2017). These methods demonstrate that utilizing
different measures of similarity between drugs and target proteins
results in improved performance compared to other methods that
are based on using only single similarity for drugs and single similar-
ity for target proteins. Moreover, a prediction method (Hao et al.,
2017) that is based on non-linear integration of similarity measures
shows better performance than the other methods based on the line-
arly combined similarity measures (Mei et al., 2013; Nascimento
et al., 2016; van Laarhoven et al., 2011). However, these studies
indicated that the DTI prediction performance of different methods
varies significantly with and depends heavily on the similarity meas-
ures used. These require development of computational methods
that optimize combination of multiple similarity measures with the
aim to improve the DTI prediction accuracy (for more detailed
information see Supplementary Material, Related work).
In this study, aiming to further improve the accuracy of DTI pre-
diction, we developed DDR, an efficient DTI prediction method that
in a novel way determines through a heuristic method an optimized
combination of similarity measures between drugs and between tar-
get proteins used in the prediction model. To predict DTIs, DDR
integrates information from different types of drug–drug and target–
target similarity measures and then, it applies a random forest (RF)
model using graph-based features. On different representative data-
sets and under various test setups, and using different performance
measure, we show that DDR significantly outperforms the other
state-of-the-arts methods by dramatically reducing the error. Using
independent sources of evidence, we verified as correct 22 out of the
top 25 DDR novel predictions. This suggests that DDR can be used




Five datasets were used to evaluate the performance of the proposed
DDR method in DTI prediction. Each dataset contains three types
of information: (i) the known DTIs for humans, (ii) multiple drug
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A frequently considered gold standard dataset (we name it
Yamanishi_08) was originally compiled by Yamanishi et al. (2008)
and was used as a reference in many studies (Ba-Alawi et al., 2016;
Lim et al., 2016; Daminelli et al., 2015; Mei et al., 2013). This data-
set contains known DTIs as retrieved from KEGG BRITE (Kanehisa
et al., 2006), BRENDA (Schomburg et al., 2004), SuperTarget
(Gunther et al., 2008) and DrugBank databases (Wishart et al.,
2008). In Yamanishi_08, the information on DTI is classified
according to the target proteins of drugs into the following four
groups: (i) enzymes (E), (ii) ion channels (IC), (iii) G-protein-coupled
receptors (GPCR) and (iv) nuclear receptors (NR). Thus,
Yamanishi_08 dataset is composed of the four datasets correspond-
ing to the classes of target proteins.
The fifth dataset is DrugBank_FDA, which is extracted from
5.0.3 version of DrugBank database (Wishart et al., 2008). We only
extracted DTI information of drugs approved by the FDA and single
human target proteins; these proteins are not part of protein com-
plexes. Table 1 summarizes the statistics of these datasets. Note
that, the ratios of known (positive) versus non-existing (not known,
negative) DTIs in all datasets are variable. This reflects practical sit-
uations where the number of true DTIs is considered to be much
smaller than that of non-interacting drug–targets.
2.1.2 Similarity measures for drugs and for target proteins
We computed multiple similarity measures for drugs and for target
proteins, respectively, where all similarity values were normalized to
the range [0, 1].
For the first four benchmark datasets from Yamanishi_08, the
similarities between drug pairs and between target protein pairs
were calculated based on information from different sources and
from Nascimento et al. (2016). For drugs, distinct chemical struc-
ture fingerprints, side-effects profiles and the Gaussian interaction
profile (GIP) were considered as drug information sources for calcu-
lation of the drug similarities. On the other hand, the similarities of
target proteins were calculated based on various amino acid
sequence profiles of proteins, as well as different parameterizations
of the Mismatch (MIS) and the Spectrum (SPEC) kernels, target pro-
teins functional annotation based on Gene Ontology (GO) terms,
proximity within the protein–protein interaction (PPI) network and
the GIP for target proteins.
For the fifth benchmark dataset, DrugBank_FDA, we computed
different similarity measures between drugs based on: different types
of molecular fingerprints, drug interaction profile, drug side-effects
profile, drug profile of the anatomical therapeutic class (ATC) cod-
ing system, drug-induced gene expression profile, drug disease pro-
files, drug pathways profiles and GIP. Furthermore, different target
protein similarity measures were calculated based on protein amino
acid sequence, their GO annotations, proximity in the PPI network,
GIP, protein domain profiles and gene expression similarity profiles
of protein encoding genes. Chemical structures of drugs were
extracted from DrugBank (Wishart et al., 2008), while the target
protein sequences were extracted from UniProt (Boutet et al., 2016).
Supplementary Table S1 shows the summary of multiple similarity
measures calculated for drugs and target proteins in the
DrugBank_FDA dataset, as well as describing their importance and
tools used to calculate them.
As a summary, all different similarity measures between drugs
and between target proteins for the first four datasets are recom-
puted/available and collected from Nascimento et al. (2016). For
DrugBank_FDA dataset, all different similarity measures between
drugs and between target proteins are calculated in this study, since




We define a set of DTIs, which consists of a set of drugs D and a
set of target proteins T, where D¼ {di, i¼1, . . ., m} and T¼ {tj,
j¼1, . . ., n}, in which m represents the number of drugs and n repre-
sents the number of target proteins. The interactions between D and
T are represented as a binary matrix Y such that if di interacts with
tj, then yij¼1, if not then yij¼0. We also define the set of similarity
matrices between drugs in D as Ds, where similarity matrices have
dimensions of m x m; we define the set of similarity matrices
between target proteins in T as Ts, where similarity matrices have
dimensions of n x n. Element values in different similarity matrices
represent how much are drugs or target proteins similar to each
other based on different measures. All elements in each matrix have
values in the range of [0, 1]. A similarity value close to 0 indicates
that two elements are not similar to each other while a similarity
value close to 1 represents the most similar elements. Given
the matrix Y, and matrices in Ds and Ts, our goal is to predict novel
(i.e. unknown) interactions in Y.
3.2 Description of the DDR method
The heterogeneous DTI graph is a weighted graph that is con-
structed with m nodes from the drug set and n nodes from the set of
target proteins. The edge between two drug nodes or two target pro-
tein nodes represents the similarity between them and is weighted by
the similarity value obtained from the similarity fusion step. The
edge between a drug and a target protein represents a known DTI
and is weighted by 1. A path structure of a path that starts at a D
node and ends up at a T node describes a subgraph that sequentially
links of drug and target protein nodes. For example, a path Drug1–
Drug2–Target1 connects the Drug1 node with the Target1 node
through the similarity edge between Drug1 and Drug2 and via the
interaction edge between Drug2 and Target1. The path structure of
this path is D–D–T. All paths with more than one edge and without
loops, starting at a D node and ending at a T node, and having the
same path structure define a path-category on the heterogeneous
DTI graph.
DDR workflow (Fig. 1) depicts several steps including: (i) infer-
ring interaction profile for new drugs and for new target proteins,
Table 1. Summary of the five datasets (Yamanishi_08 and DrugBank_FDA) used in this study
Datasets Target classes Number of drugs Number of target proteins Number of known DTIs
Yamanishi_08 NR 54 26 90
GPCR 223 95 635
IC 210 204 1476
E 445 664 2926
DrugBank_FDA Multi-class 1482 1408 9881
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(ii) similarity measure selection, (iii) similarity fusion, (iv) path-cate-
gory-based features extraction, (v) building DTI prediction model
using RF.
3.2.1 Inferring interaction profile
Inferring the DTIs profiles for new drugs and target proteins is used
only with the GIP similarity calculation. A drug is called new if it
does not have any known target protein to interact with, while a tar-
get protein is called new if it is not targeted by any known drug.
Since the GIP similarity is constructed based on training DTI data
only, the GIP similarity cannot be computed for drugs or target pro-
teins that do not have known DTIs in the training data. So, we
enhance the GIP similarity calculation by inferring interaction pro-
files for new drugs and for new target proteins, in cases where DTIs
for drugs or for target proteins are missing from the training data.
This inference is made based on the interaction profiles of such
drugs or target proteins. Drugs (or target proteins) with high similar-
ities to a new drug (or a new target protein) are said to be the neigh-
bors of the drug (the target protein). This interaction profile
inferring technique is based on Mei et al. (2013). For example, the
inferred value of interaction for a new drug with a specific target
protein is represented as the ratio of the sum of similarity values for
drug neighbors interacting with this target protein relative to the
total sum of all neighbors’ similarity values. For DDR, we subjec-
tively set the number of neighbors to 5.
3.2.2 Similarity selection: selection of an optimized set of similarities
Combining all similarity types may introduce noise in the data as
some similarities have more information than others. In order to
select a more robust similarity set, we implement similarity selection
procedure (Supplementary Figure S1) that is able to select a set of
informative and less-redundant set of similarities for drugs and for
target proteins, separately. This is done through a heuristic process,
where a subset of similarity measures is selected forming an
optimized (possibly the best) combination of similarities for our
problem.
To select set of informative similarities, our procedure goes as
follows:
(i) Calculate the average entropy for each similarity matrix to
determine how much information each similarity carries. For a simi-
larity matrix M (target–target similarity or drug–drug similarity) of
size k  k, where k represents the number of drugs (or target pro-










After that, we average the entropy values of all matrix rows to get
the final average entropy value that describes how informative a
similarity matrix is. (ii) Rank the matrices according to their average
entropy values in ascending order. The lower the average entropy
value is the less random information the similarity matrix carries.
Then, remove similarity matrices with high average entropy that
contain more random information with average entropy value
greater than c1log(k), where c1 is a constant that controls how much
information each similarity carries; thus, c1 controls level of entropy
to be selected; log(k) represents the maximum entropy value. (iii)
Calculate the pairwise similarity measure between similarity matri-
ces from different data sources, based on the Euclidean distance, as
follows. To assess the information overlap between any two similar-
ity matrices, we constructed the pairwise similarity matrix between
all similarity measures based on Euclidean distance as follows: given
two matrices for similarity measures A and B, we reorganize each
similarity matrix into vectors (VA and VB) and then compute the
Euclidean distance d as
d ¼
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiXk2
i¼1 VAi  VBið Þ
2:
r
We converted distance values to similarity Es as
Es ¼ 1
1 þ d :
(iv) After obtaining a set of informative similarities matrices, the
redundant similarity matrices are removed as follows: the procedure
starts with the similarity measure matrix having the lowest average
entropy value and eliminates all other similarity measure matrices
with Es value larger than a threshold c2. After that, the procedure
continues with the next similarity matrix in the ranked list until the
whole list of the similarity matrices is exhausted. At the end, the
remaining list of similarity measures is reported as the selected set
with small redundancy of informative similarity measures for drugs
and target proteins. In this study, we subjectively set c1 to 0.7 and c2
to 0.6. We applied this procedure to select the set of informative
less-redundant similarity measures of drugs and target proteins,
separately.
3.2.3 Similarity fusion
Given the selected subsets of similarity measures obtained previously
for drugs and for target proteins, respectively, the goal of the simi-
larity fusion step is to combine multiple similarity measures into one
final composite similarity that captures the necessary information
Fig. 1. Flowchart of DDR method. DDR consists of several steps including: (i)
Similarity selection, where a subset of similarity measures is selected in a
heuristic process. (ii) Similarity fusion, with the goal to combine the selected
similarity measures into one final composite similarity that combines infor-
mation from similarities determined in (i). (iii) Path-category-based feature
extraction, where the feature vector corresponds to drug and target protein
pairs, i.e. for ðdi ; tj Þ pair, features are determined as the vector composed of
the 12 (i, j) elements obtained by two graph-based scores, namely, n1(h, i, j)
and n2(h, i, j) for each specific path-category Ch, h¼1, 2, . . ., 6. (iv) Building
DTI prediction model using RF, where both positive and negative data are
provided; positive data contain known links between drugs and target pro-
teins and represent positive labels, while negative data contain unknown DTI
links that are treated as negative labels
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from different similarities. Thus, given a set of multiple similarity
measures for drugs and for target proteins, respectively, we com-
puted the final fused similarity measure following the similarity net-
work fusion (SNF) method developed in Wang et al. (2014). We
represent each similarity measure by k  k similarity matrix
M¼ (mi, j), where mi, j equals to the similarity value between di/dj or
ti/tj indicating how much they are similar.
The SNF combines multiple similarity measures into a single
fused similarity by a nonlinear method based on message-passing
theory. It iteratively updates every similarity network with informa-
tion from the other networks, using K-nearest neighbors, making it
more similar to the others. The SNF method can capture common as
well as complementary information across different measures of
similarities. We applied the SNF method to integrate multiple drug–
drug similarities and target–target similarities, separately.
3.2.4 Path-category-based features
After obtaining the combined similarity for drugs and for target pro-
teins, respectively, we augmented the combined similarities with the
known DTIs to construct a heterogeneous DTI graph. Based on this
heterogeneous graph, we extracted 12 path-category-based features
that we used to build a DTI prediction model. In this study, we work
with path-categories of lengths 2 and 3 (but not longer, because of the
computational cost). When we restrict paths to start at drug nodes and
end at target protein nodes, there are only two path-categories with
paths of length 2, having path structures (D–D–T) and (D–T–T),
and four path-categories with paths of length 3, having path structures
(D–D–D–T), (D–D–T–T), (D–T–D–T) and (D–T–T–T). Thus, we will
consider these six path-categories through which drug nodes could
connect to target protein nodes. We define matrices S1h and S2h associ-
ated with each path-category Ch, h¼1, 2, . . ., 6, that we consider. To
do this, we start with a given drug di to reach a given target protein tj
through a specific path-category Ch. We restrict traversing the graph to
retrieve all paths passing only through the K-nearest neighbors of drugs
to di and only through the K-nearest neighbors of target proteins to tj.
In this study, we subjectively set the number of nearest neighbors K to
5. The set of such paths we denote as Rijh. Next, for each path pq from
Rijh we calculate an edge-weight product value s obtained by multiply-
ing all weights wx of edges of pq as follows:
s h; i; j; qð Þ ¼
Y
8wx 2 pq ; pq 2 Rijh
wx:
Using the s values calculated for all paths pq from Rijh, we calculate
scores s1 and s2 as follows:
s1 h; i; jð Þ ¼
X
8q:pq 2 Rijh
s h; i; j; qð Þ:
Thus, for each path-category Ch, we obtained a matrix S1h with ele-
ments s1(h, i, j). Also, for each path-category Ch, we obtained a
matrix S2h with elements s2(h, i, j) determined as:
s2 h; i; jð Þ ¼ max8q:pq 2 Rijh s h; i; j;qð Þð Þ:
Finally, we normalized matrices S1h and S2h to adjust for the overall
connectivity of the network, where the elements of the normalized
matrices are:
nr h; i; jð Þ ¼ sr h; i; jð ÞP
jsr h; i; jð Þ
;
where r ¼ 1 or 2. The normalized matrices are now N1h with elements
n1(h, i, j) and N2h with elements n2(h, i, j) calculated as shown above.
In total, DDR defines 12 different path-category-based matrices,
namely N1h, N2h, where h¼1, 2, . . ., 6, which contain feature val-
ues. These matrices have the same number of rows (corresponding
to drugs) and the same number of columns (corresponding to target
proteins).
3.2.5 RF classification model for DTI prediction
To predict DTI, DDR utilizes supervised machine learning model
based on the RF classifier (Ho, 1995). RF has been shown to be an
effective tool in prediction, as it runs efficiently on large datasets
and is less prone to over-fitting. We implemented the RF predictive
model using scikit-learn (Pedregosa et al., 2011). The inputs to the
RF correspond to drug and target protein pairs, i.e. for the ðdi; tjÞ
pair, the feature vector is determined as the vector composed of the
(i, j) elements of matrices N1h and N2h. Since h¼1, 2, . . ., 6, these
feature vectors contain 12 elements each. In order to learn from
highly imbalanced data, in this study we adjusted the RF class
weights to be inversely proportional to the number of class labels for
each class in the training data. Two important parameters are set
when building the RF model: The number of trees in the forest
(n_estimators) was set to be in the range of [100, 600] trees and a
function to measure the quality of a split (criterion) where we used
Gini index and entropy based functions. To construct the prediction
model, both positive and negative data are provided as either known
DTIs to represent positive labels or unknown DTIs that are treated
as negative labels.
3.3 Experimental setting and performance evaluation
To facilitate the comparison with other methods, we performed
cross-validation (CV) and hold-out type tests. First, we evaluated
the performance of the DDR method for DTI prediction using CV
experiments obtained under three different settings of prediction
tasks as in Pahikkala et al. (2015). The experiments were performed
separately for each dataset used in this study (the four gold standard
datasets from Yamanishi_08 and the DrugBank_FDA dataset). The
three prediction settings correspond to the cases when: (a) the drugs
are new, (b) the target proteins are new and (c) the drugs and their
target proteins are known but all interactions between them are not
necessarily known. Cases (a) and (b) correspond to the situation
when there are no DTIs in the training data for such drugs or target
proteins, while case (c) corresponds to the situation when there are
DTI in the training data for such drugs or target proteins. We name
settings (a), (b) and (c) as SD, ST and SP, respectively.
For each dataset, a prediction model in each setting is built using
a dataset of positive and negative labels split into the training and
testing sets. This procedure is followed for each fold in 10-fold CV
and the whole process is repeated 5 times, each time with a different
random seed used for random selection for the split into training
and testing sets. In each fold of the CV process, all interactions yij in
Y matrix that belong to the testing set in that fold are set to zero, i.e.
they were excluded from consideration. The resulting matrix with
removed testing DTIs is Ytrain. In each fold, the model learns interac-
tions from Ytrain and then constructs the GIP similarity. Then, we
select the best set of similarity measures (according to DDR’s heuris-
tic procedure). After that, we use all selected similarities separately
for drugs and separately for target proteins, to generate a fused simi-
larity matrix for drugs and a fused similarity matrix for target pro-
teins. Based on Ytrain and the two generated fused similarity
matrices, we construct a heterogeneous DTI graph, where we extract
path-category-based features as explained before, and score them
using two graph-based scores. Finally, we train the RF model on the
1168 R.S.Olayan et al.
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training set for that fold until the best area under the precision-recall
(AUPR) is obtained. Then, using the trained model, we predict and
evaluate predictions on the testing set for that fold.
Moreover, we performed the hold-out tests derived from 9881
DTIs from DrugBank_FDA dataset under the same SD, ST and SP set-
tings of prediction tasks. In the hold-out test, we split the data into
80% for training and 20% for testing.
For each prediction model, at each fold in case of CV, we consid-
ered the following evaluation metrics: Based on the methods scores,
we define true positive (TP), false negative (FN), false positive (FP)








We construct precision-recall curve based on different precision and
recall values at different cut-offs. Also, we construct the area under
the ROC curve (AUC) at various threshold settings, based on differ-
ent recall values, and false positive rate (FPR) values, calculated as
1 specificity. Then, we calculate the AUPR and AUC, where the
values of AUPR and AUC, separately, over 5-repeats of 10-fold CVs
are averaged and reported as the measures of the model performance
for each dataset. As the positive and negative data in the datasets
used in this study are highly imbalanced, AUPR metric provides a
better quality estimate, since it punishes more heavily the existence
of FPs than is the case with AUC. Thus, in this study, we mainly
used AUPR values to evaluate the performance of the methods,
though we also reported the AUC values in Supplementary Material.
As a summary, for the purpose of the fair comparison with the other
methods, all methods are subjected to the exactly same conditions of
testing and the same datasets [(i) the five trials of 10-fold CV and the
same datasets, Yamanishi_08 and DrugBank_FDA dataset and (ii) the
same hold-out test based on DrugBank_FDA]. We point out that all
methods are evaluated using the same data splits to avoid any type of
unwanted bias. Also, we used only training data to develop models.
4 Results
4.1 Comparisons with the state-of-the-art algorithms
First, we compare our proposed DDR method with the following
state-of-the-art methods (for more detailed information see
Supplementary Material, Related work) namely: COSINE (Lim et al.,
2016), DNILMF (Hao et al., 2017), NRLMF (Liu et al., 2016),
KRONRLS-MKL (Nascimento et al., 2016) and BLM-NII (Mei et al.,
2013) under the same conditions for all methods, i.e. under the three
prediction settings (SP, SD and ST) and over five trials of 10-fold CV
based on Yamanishi_08 and DrugBank_FDA datasets.
We show that DDR, using 5-repeats of 10-fold CV, achieves higher
AUPR values compared with the other methods (Fig. 2). In terms of
AUPR, over the five different datasets, DDR, DNILMF, NRLMF,
KRONRLS-MKL, COSINE and BLM-NII achieved weighted average
of AUPR score under the three different prediction tasks settings as (SP:
71%, SD: 53%, ST: 52%), (SP: 56%, SD: 26%, ST: 37%), (SP: 50%,
SD: 29%, ST: 39%), (SP: 52%, SD: 20%, ST: 17%), (SD: 32%) and (SP:
35%, SD: 14%, ST: 25%), respectively. The weighted average of





where 5 is the number of datasets used in this study, TS is the total
number of samples in all datasets and NSi is the number of samples
in i-th dataset.
It should be noted that the COSINE method is specifically tailored
for the SD setting to find target proteins of new drugs with little to no
available interaction data; thus, only its results for the SD setting are
shown. Also, we show that DDR, using 5-repeats of 10-fold CV,
achieves higher AUC values compared to the other methods under three
prediction tasks and over the five different datasets (Supplementary
Table S2). Thus, in terms of AUC, over the five different datasets,
DDR, DNILMF, NRLMF, KRONRLS-MKL, COSINE and BLM-NII
achieved weighted average of AUC score under the three different pre-
diction tasks settings as (SP: 96%, SD: 90%, ST: 89%), (SP: 95%, SD:
87%, ST: 85%), (SP: 94%, SD: 85%, ST: 84%), (SP: 89%, SD: 77%, ST:
83%), (SD: 86%) and (SP: 91%, SD: 73%, ST: 80%), respectively.
To show more clearly the accuracy improvement by DDR, we
define the AUPR score error E as
E ¼ 1  AUPR
while the relative reduction of the AUPR score error of method 1 rel-
ative to method 2 we defined as
DE ¼ ðE2  E1Þ=E2;
Fig. 2. Comparison results (in terms of AUPR scores) of DDR with the five
state of the art methods (DNILMF, NRLMF, KRONRLS-MKL, COSINE and
BLM-NII) using 5-repeats of 10-fold CV. Results are obtained under three pre-
diction tasks (SP, SD and ST) over all datasets (NR, GPCR, IC, E and
DrugBank_FDA) used in this study. The results for DNILMF, NRLMF,
KRONRLS-MKL, COSINE and BLM-NII are obtained using the best parameters
reported in the respective publications
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where E1 and E2 are determined for method 1 and method 2, respec-
tively. Based on individual AUPR values reported from 5-repeats of
10-fold CV experiments, we also calculated the relative reduction of
the AUPR error obtained by DDR relative to the next best method
across all different testing settings for each dataset. When predicting
unknown DTI pairs, as in the SP setting, DDR significantly reduces
AUPR error relative to the next best method by 39%, 30%, 38%,
27% and 33% for NR, GPCR, IC, E and DrugBank_FDA datasets,
respectively. For predicting DTIs for new drugs (SD setting), DDR
significantly reduces AUPR error relative to the next best method by
36%, 38%, 51%, 58% and 20%, for NR, GPCR, IC, E and
DrugBank_FDA datasets, respectively. Finally, for predicting new
target proteins (ST setting), DDR significantly reduces AUPR error
relative to the next best method by 25%, 11%, 49%, 25% and
21%, for NR, GPCR, IC, E and DrugBank_FDA dataset, respec-
tively. As a result, we demonstrate that DDR, reported from 5-
repeats of 10-fold CV experiments, achieves significantly more accu-
rate results than the other methods by achieving higher rank
(Supplementary Table S3) on different datasets and in all three set-
tings. We also demonstrated that DDR performs significantly better
than the other existing methods when known DTIs are missing in
the training data. This shows practical assessments of the predictive
power of DDR for real scenarios of DTI prediction, as in finding tar-
get proteins for new drugs (SD setting) with no available information
about interactions and predicting drugs for new target proteins (ST
setting) (Supplementary Table S3).
Moreover, we demonstrated that on weighted average over five
datasets, reported from 5-repeats of 10-fold CV experiments, DDR
reduces the AUPR score error relative to the next best method by
34% for predicting DTIs as in setting (SP), by 31% for predicting
DTIs as in setting (SD) and by 23% for predicting DTIs as in setting
(ST). This demonstrates that DDR significantly reduces the AUPR
score error compared to the other start-of-the-art methods.
In general, based on our prediction results (Fig. 2), we observe
that the results with the prediction model built for each specific class
of target proteins (i.e. NR, GPCR, IC, E) are better than the results
obtained by building a general model for multiple different target
protein classes as in the case of DrugBank_FDA data. This is
because each class of target proteins (NR, IC, GPCR, E) has its com-
mon characteristics that make them different from other classes.
Thus, it is reasonable to expect that the well-designed and trained
DTI predictor will capture some of these characteristics. In this way,
the DTI prediction models will also be more specific and tuned to
the target protein class for which they were developed and less tuned
for the other target protein classes. Our results obtained for predict-
ing DTIs using DrugBank_FDA data confirmed that even in this
case DDR significantly outperformed all other state-of-the-art meth-
ods used in the comparison.
We also performed test on hold-out data using DrugBank_FDA
dataset. These tests show that DDR achieves higher AUPR and AUC
values compared with the other methods under the three prediction
settings (Supplementary Table S4). We demonstrate that based on
AUPR values, reported from hold-out tests, the reduction of the
AUPR error for DDR relative to the next best method across all dif-
ferent testing settings for DrugBank_FDA dataset are 44% in the SP
setting, 21% in the SD setting and 29% in the ST setting.
4.2 Effect of similarity measures on the DDR
performance
Similarity between drugs or target proteins plays the most crucial
role when trying to predict DTIs for new drugs or new target
proteins. Different similarity measures describe data instances differ-
ently. Several studies have highlighted the importance of selecting
the proper similarity and integrating several similarity types to cap-
ture complementary information from several sources (Hao et al.,
2017; Nascimento et al., 2016). The proof is the improved accuracy
of DTI predictions over single adopted similarity (one for target pro-
teins, one for drugs), and this is why the combining multiple types of
similarities is important. We demonstrated that a suitable combina-
tion of few similarity measures results in higher accuracy of DTI pre-
dictions than when many or all similarity measures are used. Thus,
the improvements DDR provide compared to the current combina-
tion strategies are that: (i) it applies non-linear similarity fusion
method to combine different similarities, (ii) it can handle any num-
ber of provided similarities and (iii) it provides a systematic frame-
work to select the most relevant non-redundant similarities. In
addition, combining multiple similarity measures into one combined
similarity reduces the time complexity and data dimensionality
needed by the DDR method compared to the case of building a clas-
sification model with multiple features, where each feature is based
on scoring a path from a drug to a target protein through each single
similarity measure between drugs and each single similarity measure
between target proteins.
Thus, our aim is to combine multiple similarity measures into
one final composite similarity that captures the necessary informa-
tion from different similarities between drugs as well as from differ-
ent similarities between target proteins. Regarding this, we show
that DDR achieves higher AUPR values compared to the other meth-
ods (Fig. 2). We also compared the DDR performance when com-
bining all similarity measures we used in this study, with the case of
combining only the similarity measures we selected in a heuristic
process. We observed that the performance of DDR when combin-
ing only selected similarities is better than when combining all simi-
larities (Supplementary Table S5).
When we examined the selected similarities over the four data-
sets in Yamanishi_08, we observed that DDR consistently selects a
similar set of similarity measures for drugs and for target proteins
(Supplementary Table S6). For the selected similarity of drugs, we
observe that the selected similarities are related to network interac-
tion profiles and drug side-effects. It has been highlighted before
that the side-effect-based similarity improves the prediction of DTIs,
where the assumption is that drugs with similar target protein bind-
ing profiles tend to cause similar side-effects, implying a direct corre-
lation between target protein binding and side-effect similarity
(Campillos et al., 2008; Vilar and Hripcsak, 2016). It has also been
shown that the interaction profiling is an effective tool that can be
used for accurate prediction of DTIs (van Laarhoven et al., 2011);
the assumption is that two drugs that interact in a similar way with
the target proteins in a known DTI network, will also interact in a
similar way with new target proteins. For selected similarities of tar-
get proteins, we observe that these similarities are constructed based
on a specific characteristic of amino acids sequence and closeness in
PPI network that have been highlighted before in different bench-
marking studies of target protein descriptors to result in a good per-
formance for DTI prediction (Cao, 2015; Deng et al., 2002;
Nascimento et al., 2016).
For the DrugBank_FDA dataset (Supplementary Table S6), DDR
selected a set of similarity measures for drugs and for target proteins,
separately. We note that the information included in different data
sources used to calculate the similarity measures between drugs
and between target proteins have highly influenced the prediction
performance for drugs interacting with multi-class target proteins
(i.e. NR, GPCR, etc.). For similarity measures of drugs and target
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proteins that have been selected in the sequential heuristic process,
we observe that these similarities are related to network interaction
profiles (van Laarhoven et al., 2011) and other genome-wide global
characteristics of drugs and of target proteins such as drug-diseases
profiles and drug-pathways profiles between drugs, drug-induced
gene expression profiles of drugs, profiles of drug ATC-codes associ-
ations, profiles of GO terms of target proteins and profiles of path-
ways of target proteins. Using such types of similarities in DTI
prediction in numerous studies proved to be effective in describing
each drug and target protein in different datasets (Chen et al.,
2012a,b; Dudley et al., 2011; Dunkel et al., 2008; Ehsani and
Drablos, 2016; Iwata et al., 2017; Pan et al., 2014; Rodriguez-
Esteban, 2016; Smith et al., 2012; van Laarhoven et al., 2011; Vilar
and Hripcsak, 2016).
4.3 Prediction and validation of novel (unknown) DTIs
To evaluate the utility of DDR, we used it to predict novel DTIs (i.e.
those that are not known to be true DTIs) in each of the five data-
sets, separately. For prediction of novel interactions, we build the
predictive model for each dataset used in this study, in which the
model is trained using all known interactions (positive labels) in all
data folds of CV, and the negative labels are split into train and test
sets as in a CV setup. As a result, all unknown DTI (negative labels)
are predicted and the top 5 ranked interactions for each dataset are
validated. To verify these novel predictions, we considered several
reference databases that contain information obtained from curated/
experimental/published results on small molecule–protein interac-
tions. Thus, we searched DrugBank (Wishart et al., 2008), KEGG
(Kanehisa et al., 2006), ChEMBL (Gaulton et al., 2012), Matador
(Gunther et al., 2008), CTD (Davis et al., 2017), T3DB (Wishart
et al., 2015) and the biomedical literature to find supporting
evidences.
In summary, we evaluated the accuracy of 25 novel DTIs pre-
dicted by our method using four datasets of Yamanashi_08 and
DrugBank_FDA dataset and confirmed 22 of these novel DTIs as
supported by other existing evidence (Table 2).
Furthermore, to demonstrate that the predictions by DDR are
not random, we additionally performed the label permutation tests
to ensure that the top 5 DTI predictions by DDR in each dataset are
Table 2. Top ranked 25 novel DTIs predicted by DDR
Drug ID Drug name Taregt protein ID Target protein name Validation source Evidence
Dataset: NR
D00348 Isotretinoin hsa6256 RXRA CTD CTD: D015474, CTD: 6256
D00585 Mifepristone hsa2099 ESR1 C and PMID C:
1166117, C: 206,
C: 1276308, PMID: 20046055
D00962 Clomiphene citrate hsa5241 PGR CTD CTD: D002996, CTD: 5241
D00182 Norethindrone hsa2099 ESR1 T3DB and PMID T3DB: T3D4745,
PMID: 23611293
D00951 Medroxyprogesterone acetate hsa2099 ESR1 DB DB: DB00603
Dataset: GPCR
D00049 Niacin hsa8843 HCAR3 DB DB: DB00627
D02910 Amiodarone hsa154 ADRB2 CTD CTD: D000638, CTD: 154
D02340 Loxapine hsa1812 DRD1 DB DB: DB00408
D00726 Metoclopramide hsa1129 CHRM2 M M: PC4168
D00674 Naratriptan hydrochloride hsa3351 HTR1B DB DB: DB00952
Dataset: IC
D02356 Verapamil hsa6833 ABCC8 PMID PMID: 21098040
D03365 Nicotine hsa1137 CHRNA4 DB DB: DB00184
D00538 Zonisamide hsa6331 SCN5A DB DB: DB00909
D02098 Proparacaine hydrochloride hsa8645 KCNK5 None None
D00775 Riluzole hsa2898 GRIK2 None None
Dataset: E
D00139 Methoxsalen hsa1543 CYP1A1 DB and PMID DB: DB00553
PMID: 15670584
D00437 Nifedipine hsa1559 CYP2C9 DB DB: DB01115
D00410 Metyrapone hsa1583 CYP11A1 CTD CTD: D008797, CTD: 1583
D00574 Aminoglutethimide hsa1589 CYP21A2 M M: PC2145
D00542 Halothane hsa1571 CYP2E1 M M: PC3562
Dataset: DrugBank_FDA
DB01589 Quazepam P47870 GABRB2 K K: D00457
DB00825 Menthol P35372 OPRM1 None None
DB00147 Pyridoxal P04798 CYP1A1 PMID PMID: 19637937
DB01544 Flunitrazepam P14867 GABRA1 CTD and K CTD: D005445, K: D01230
DB02546 Vorinostat P56524 HDAC4 CTD and C CTD: C111237, CTD: 9759
C: 98,
C: 3524
Note: Most of the top novel interactions (highest prediction score) are confirmed as supported by other existing evidences (public databases or literature) where
the following annotation is used to demarcate the source of confirmatory information.
C, ChEMBL; CTD, Comparative Toxicogenomics Database; DB, DrugBank; M, MATADOR; K, KEGG; PMID, PubMed; PC, PubChem Compound.
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not predicted by chance. To do so, we performed the following: we
randomly shuffled the network labels (known and unknown) 100
times to produce different 100 random networks. Then, we per-
formed SP DTI prediction setup on each network. For each dataset
and for each novel DTI in the top 5 DTIs based on that dataset, we
calculated P-value as the percentage of a given novel DTI being
ranked in the top 5 DTIs in the 100 random networks. We demon-
strated that all predicted novel DTIs have significant P-values <0.05
(Supplementary Table S7). Thus, in addition to having DDR novel
DTI prediction validated based on other sources, results from the
label permutation tests also confirm the reliability of DDR novel
DTI predictions.
5 Discussion
This study introduces a novel DTI prediction method, DDR, which
utilizes a heterogeneous drug–target graph that contains information
about various similarities between drugs and similarities between
proteins as drug targets. On different representative datasets, under
various test setups, and using AUPR and AUC as the performance
measures, we show that DDR clearly outperforms the other state-of-
the-art methods we used in the comparison. For these we used CV
and hold-out tests. DDR achieves notably higher AUPR values com-
pared to other methods, thus significantly reducing the AUPR score
error relative to the next best method.
Moreover, on different datasets and in all three task settings we
demonstrate that DDR produces significantly more accurate results
than the other methods by achieving higher rank, based on AUPR
values. We also demonstrated that DDR performs significantly bet-
ter than the other existing methods when known DTIs are missing in
the training data. This shows practical assessments of the predictive
power of DDR for real scenarios of DTI prediction, as in finding tar-
get proteins for new drugs (SD setting) with no available information
about interactions and predicting drugs for target proteins that are
new (ST setting).
When we compared DDR performance in case of combining all
similarity measures we used in this study with the case of combining
only the similarity measures we selected through our heuristic
method, we observed that the performance of DDR with selected
similarities is better than when combining all similarities.
We observed that the best second method in predicting DTI as in
SP setting, based on the weighted average of AUPR results over the
five different datasets is the DNILMF method. This is due to the
method followed by DNILMF in employing the nonlinear combina-
tion technique of multiple similarity measures for drugs and for tar-
get proteins, as well as smoothing the predictions of new drugs and
new target proteins by incorporating neighbor information based on
the assumption that similar drugs (or target proteins) may contribute
to the accuracy of the predictions for their neighbors. On the other
hand, in predicting DTIs, we observed that the second best method,
based on the weighted average of AUPR results over the five differ-
ent datasets in the ST and SD setting, are the NRLMF and COSINE,
respectively.
As the current implementation of DDR handles only binary
DTI data with the goal of classifying a given DTI as binding (label-
¼1) or non-binding (label¼0), in future, we plan to extend
the functionality of DDR to handle continuous DTI data (i.e.
continuous values of binding affinities of drugs and target proteins,
He et al., 2017).
6 Conclusion
We presented our method (DDR) that is based on the use of a heter-
ogeneous graph containing information about known DTIs, as well
as similarities between drugs and similarities between target proteins
obtained from different data sources. DDR utilizes graph mining
and machine learning techniques. It is capable of utilizing different
similarity measures between drugs, as well as between target pro-
teins. DDR applied non-linear similarity fusion method to combine
different similarities for drugs and target proteins. Before applying
the combined similarity method, DDR performed a pre-processing
step where a subset of similarity types is selected in a heuristic proc-
ess. This is done to select the best combination of similarities for the
tasks in question since using all similarity types introduces noise.
We demonstrated that DDR achieves significantly more accurate
results than the other state-of-the-art methods under different pre-
diction tasks settings and using different datasets and different meth-
ods of performance evaluation. Finally, we evaluated the accuracy
of 25 novel DTIs predicted by our method and confirmed 22 of these
novel DTIs as supported by other existing evidences. Thus, DDR
proved its practical utility by validating predictions of novel DTIs
over different datasets, suggesting that DDR can be used as an effi-
cient method to identify correct DTIs.
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